Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2707]

Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia...

Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany

Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise ( Prof Stephan Stilgenbauer - University of Ulm, Ulm, Germany )

Study underscores promise of targeted therapies as first-line approach for...

Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano...

Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia ( Dr Alessandra Tedeschi - Azienda Ospedaliera Niguarda Cà Granda Milano, Milano, Italy )

First targeted therapy for multiple myeloma effective against hard-to-treat...

Dr Torben Plesner - Vejle Hospital, University of Southern Denmark, Vejle...

First targeted therapy for multiple myeloma effective against hard-to-treat disease ( Dr Torben Plesner - Vejle Hospital, University of Southern Denmark, Vejle, Denmark )

First targeted therapy for genetically defined subset of patients with acute...

Dr Richard M. Stone - Dana-Farber Cancer Institute, Boston, USA

First targeted therapy for genetically defined subset of patients with acute myeloid leukaemia significantly improves survival ( Dr Richard M. Stone - Dana-Farber Cancer Institute, Boston, USA )

Study finds new use for rituximab in acute lymphoblastic leukaemia

Prof Sébastien Maury - Hôpital Henri Mondor, Créteil, France

Study finds new use for rituximab in acute lymphoblastic leukaemia ( Prof Sébastien Maury - Hôpital Henri Mondor, Créteil, France )

First targeted therapy for multiple myeloma effective against hard-to-treat...

Dr Torben Plesner - Vejle Hospital, Vejle, Denmark

First targeted therapy for multiple myeloma effective against hard-to-treat disease ( Dr Torben Plesner - Vejle Hospital, Vejle, Denmark )

First targeted therapy for genetically defined subset with acute myeloid...

Dr Richard Stone - Dana Farber Cancer Institute, Boston, USA

First targeted therapy for genetically defined subset with acute myeloid leukaemia significantly improves survival ( Dr Richard Stone - Dana Farber Cancer Institute, Boston, USA )

Immunotherapy makes patients’ tumours "melt away"

Dr Joshua Brody - Mount Sinai Medical Center, New York, USA

Immunotherapy makes patients’ tumours "melt away" ( Dr Joshua Brody - Mount Sinai Medical Center, New York, USA )

Genetic variant that signifies higher risk for avascular necrosis in children...

Dr Peter D. Cole - Albert Einstein College of Medicine, New York, USA

Genetic variant that signifies higher risk for avascular necrosis in children with acute leukaemia ( Dr Peter D. Cole - Albert Einstein College of Medicine, New York, USA )

Tosedostat for elderly acute myeloid leukaemia

Dr Giuseppe Visani - Ospedale S. Salvatore, Pesaro, Italy

Tosedostat for elderly acute myeloid leukaemia ( Dr Giuseppe Visani - Ospedale S. Salvatore, Pesaro, Italy )

Anti-Bcl2 therapy shows promise for relapsed/refractory multiple myeloma

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

$Anti-Bcl2 therapy shows promise for relapsed/refractory multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )$

Daratumumab for multiple myeloma

Prof Sagar Lonial - Emory University School of Medicine, Atlanta, USA

Daratumumab for multiple myeloma ( Prof Sagar Lonial - Emory University School of Medicine, Atlanta, USA )

More from ecancer